Study S000942

A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Phase 2 Study of Efficacy and Safety of Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07046819
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 120
Start: 2026-06-11
Primary completion: 2027-07-30
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions: Metabolic Alcohol-associated Liver Disease; Alcohol Use Disorder
Interventions: DRUG:Tirzepatide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:002246-AA

Registered primary outcomes

Metabolic improvement from baseline as measured by percentage reduction of body weight and reduction in liver steatosis from baseline as measured by percentage reduction in Fibroscan controlled attenuation parameter (CAP) score. [Change from baseline to week 12]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014066	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T, Molecular metabolism	2018	Randomized trial	PMID 30473097 DOI	registry reference BACKGROUND:30473097